PTC Therapeutics, Inc. (PTCT) Financials
Key financial figures for PTC Therapeutics, Inc. (Q3 2026).
PTC Therapeutics Q3 2026 revenue of $357.8M (vs $211.0M a year ago) with Sephience at $181.9M; full-year revenue guidance raised, GAAP net loss of $51.7M on a $111.0M acquired IPR&D charge. Total revenue was $357.8M vs $211.0M in Q3 2025, including $275.9M of net product revenue (vs $131.0M) and $81.7M of Evrysdi royalty revenue (vs $70.8M); revenue was above the FMP estimate of $306.4M. Sephience net product revenue was $181.9M, up 20% from Q2 2026, with over 2,000 active patients worldwide. Translarna was $48.5M (vs $50.7M) and Emflaza $25.1M (vs $35.2M). GAAP net loss was $51.7M, or $0.62 per diluted share, vs net income of $15.9M ($0.20) a year ago; EPS was below the FMP estimate of $0.14. On the outlook: Full-year 2026 total revenue raised to $1.29B to $1.32B; total product revenue raised to $960M to $990M from $850M to $950M; GAAP R&D and SG&A expense guidance unchanged at $775M to $815M; non-GAAP R&D and SG&A unchanged at $680M to $720M. Figures are for Q3 2026, as PTC Therapeutics, Inc. reported them.
- Revenue
- $358M
- Net Income
- -$52M
- EPS
- $-0.62
- Total Assets
- $3.2B
- Operating Cash Flow
- -$25M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $358M | -$52M | -$0.62 | 7.02% | -$28M |
| Q2 FY2026 | $361M | $83M | $0.92 | 41.32% | $122M |
| Q1 FY2026 | $273M | -$3M | -$0.03 | 16.84% | -$60M |
| Q4 FY2025 | $165M | -$135M | -$1.67 | -49.57% | -$72M |
| Q3 FY2025 | $211M | $16M | $0.20 | 1.43% | -$323M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.7B | $683M | $7.78 | 49.49% | $411M |
| FY2024 | $807M | -$363M | -$4.73 | -37.5% | -$182M |
| FY2023 | $938M | -$627M | -$8.37 | -46.86% | -$279M |
Frequently asked questions
What was PTC Therapeutics, Inc.'s revenue last quarter?
PTC Therapeutics, Inc. reported revenue of $357.8 million for Q3 FY2026, up 69.6% from the same period a year earlier.
Is PTC Therapeutics, Inc. profitable?
Not in its most recent reported period. PTC Therapeutics, Inc. reported a net loss of $51.7 million for Q3 FY2026, a net margin of -14.45% on revenue.
How has PTC Therapeutics, Inc.'s margin trended?
Operating margin was 7.02% in Q3 FY2026, compared with 1.43% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did PTC Therapeutics, Inc. generate?
PTC Therapeutics, Inc. generated free cash flow of -$28.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for PTC Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.